There are a lot of physicians who still believe that TRT will exacerbate prostate cancer, and that people on TRT can take AIs. What does research actually tell us about this? Why should you consider optimization? What is the relationship between sex hormone binding globulin and testosterone? On this episode, double board certified physician and PhD candidate, Dr. Nick Sakkas goes deep on these questions and provides insights backed by some interesting recent research. Testosterone induces cell apoptosis of prostate cancer and inhibits proliferation. -Dr. Nick Sakkas Three Takeaways You have to understand how SHBG is going to affect the testosterone molecularly before you do TRT. Undergoing TRT and taking an AI suppresses estrogen and puts you at an extreme risk of developing cardiac hypertrophy and organ damage in the long-term. On prostate cancer: low testosterone levels are associated with a poor prognosis.   At the start of the show, Dr. Nick shared how he got started, and we talked about sex hormone binding globulin and why its levels will determine the effectiveness of TRT. Next, we talked about a huge misconception people have about prostate cancer and TRT, and what the research really says about it. We also discussed what so many doctors are getting wrong about estrogen with optimization patients, and how you should really consider AIs. Towards the end, we talked about androgens and calcium retention. We also discussed: Why it’s critical that you do not suppress estrogen How optimization changes everything How often a healthy TRT patient should get their arteries checked Angiotensin blockers   Why Vitamin K2 supplements will save your heart and brain Hormone replacement will change your life in many ways, including inhibiting the proliferation of prostate cancer. When it comes to TRT, it’s not wise to rush into taking an AI. Wait for both your estrogen and testosterone to stabilize, for between 6 months to a year. It’s also necessary to consider your sex hormone binding globulin. It is the center of all hormonal evaluation, and must be considered before undergoing TRT.   Guest Bio Dr. Sakkas is a physician, researcher and PhD candidate in the field of molecular endicronology. To get in touch, find him on Facebook https://www.facebook.com/nikosakk88 or email nikosakkis.gmail.com.